NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News $40.55 -2.78 (-6.42%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$40.24▼$41.5950-Day Range$34.73▼$43.3352-Week Range$32.69▼$48.82Volume5.55 million shsAverage Volume1.13 million shsMarket Capitalization$5.80 billionP/E RatioN/ADividend YieldN/APrice Target$46.64 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ionis Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside15.0% Upside$46.64 Price TargetShort InterestBearish5.11% of Float Sold ShortDividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.34Based on 8 Articles This WeekInsider TradingSelling Shares$286,134 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.54) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 starsMedical Sector802nd out of 981 stocksPharmaceutical Preparations Industry399th out of 477 stocks 2.2 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 5 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.64, Ionis Pharmaceuticals has a forecasted upside of 15.0% from its current price of $40.55.Amount of Analyst CoverageIonis Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.11% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 1.9 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ionis Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 10 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $286,134.00 in company stock.Percentage Held by InsidersOnly 2.36% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions87.32% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.54) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -17.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -17.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 10.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ionis Pharmaceuticals (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.Read More Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Stock News HeadlinesJune 7, 2023 | msn.comWhy Ionis Pharmaceutical Shares Are Trading Lower WednesdayJune 7, 2023 | markets.businessinsider.comAnalyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway'June 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 7, 2023 | msn.comIonis Pharma slips on convertible debt offeringJune 7, 2023 | realmoney.thestreet.comI've Got My Eye On Ionis Pharmaceuticals for Higher HighsJune 2, 2023 | finance.yahoo.comIonis Pharmaceuticals (IONS) Up 19.3% Since Last Earnings Report: Can It Continue?June 1, 2023 | finance.yahoo.comIonis announces positive donidalorsen late-stage clinical progress in HAEMay 26, 2023 | americanbankingnews.comPatrick R. O'neil Sells 1,527 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockJune 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 26, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Brett P. Monia Sells 4,931 SharesMay 24, 2023 | finance.yahoo.comIonis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79May 24, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Hold" from BrokeragesMay 18, 2023 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Now Covered by StockNews.comMay 10, 2023 | finance.yahoo.comIonis to host 2023 virtual Annual Meeting of StockholdersMay 8, 2023 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Stock Rating Reaffirmed by VNET GroupMay 4, 2023 | msn.comBarclays Maintains Ionis Pharmaceuticals (IONS) Equal-Weight RecommendationMay 4, 2023 | marketwatch.com8-K: IONIS PHARMACEUTICALS INCMay 4, 2023 | finance.yahoo.comIonis (IONS) Q1 Earnings Surpass Estimates, Sales MatchMay 4, 2023 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded to "Neutral" at CitigroupMay 4, 2023 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) PT Lowered to $37.00 at BarclaysMay 3, 2023 | finance.yahoo.comHere's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q1 EarningsMay 3, 2023 | msn.comRecap: Ionis Pharmaceuticals Q1 EarningsApril 29, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasted to Earn FY2024 Earnings of ($3.93) Per ShareApril 29, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Hold" from AnalystsApril 28, 2023 | americanbankingnews.comSVB Leerink Analysts Lift Earnings Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)April 27, 2023 | finance.yahoo.comIonis Pharmaceuticals Sees Progress on "Multiple Fronts"April 27, 2023 | finance.yahoo.comAvalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseSee More Headlines IONS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IONS Company Calendar Last Earnings5/03/2023Today6/07/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees660Year FoundedN/APrice Target and Rating Average Stock Price Forecast$46.64 High Stock Price Forecast$67.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+15.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,720,000.00 Net Margins-56.85% Pretax Margin-53.18% Return on Equity-57.58% Return on Assets-12.74% Debt Debt-to-Equity Ratio2.42 Current Ratio9.81 Quick Ratio9.72 Sales & Book Value Annual Sales$575.97 million Price / Sales10.07 Cash FlowN/A Price / Cash FlowN/A Book Value$4.03 per share Price / Book10.06Miscellaneous Outstanding Shares143,100,000Free Float139,723,000Market Cap$5.80 billion OptionableOptionable Beta0.53 Key ExecutivesBrett P. MoniaChief Executive Officer & DirectorOnaiza Cadoret-ManierEVP, Chief Product Strategy & Operations OfficerElizabeth L. HougenChief Financial Officer & Executive VP-FinanceC. Frank BennettChief Scientific Officer & Executive VPSanjay BhanotChief Medical Officer & SVPKey CompetitorsAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLAmicus TherapeuticsNASDAQ:FOLDImmunoGenNASDAQ:IMGNUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 3,992 shares on 5/26/2023Ownership: 0.007%Patrick R O'neilSold 1,527 sharesTotal: $63,675.90 ($41.70/share)Brett P MoniaSold 4,931 sharesTotal: $197,930.34 ($40.14/share)New York State Common Retirement FundSold 3,503,500 shares on 5/18/2023Ownership: 0.094%International Biotechnology Trust PLCBought 43,000 shares on 5/18/2023Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions IONS Stock - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price forecast for 2023? 10 analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $27.00 to $67.00. On average, they expect the company's share price to reach $46.64 in the next year. This suggests a possible upside of 15.0% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2023? Ionis Pharmaceuticals' stock was trading at $37.77 on January 1st, 2023. Since then, IONS stock has increased by 7.4% and is now trading at $40.55. View the best growth stocks for 2023 here. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our IONS earnings forecast. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.13. The firm had revenue of $131 million for the quarter, compared to the consensus estimate of $126.88 million. Ionis Pharmaceuticals had a negative net margin of 56.85% and a negative trailing twelve-month return on equity of 57.58%. The business's quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.46) earnings per share. What ETFs hold Ionis Pharmaceuticals' stock? ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Direxion mRNA ETF (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP) and VanEck Morningstar SMID Moat ETF (SMOT). What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $597.65 million. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Clearbridge Investments LLC (3.77%), Price T Rowe Associates Inc. MD (2.75%), ARK Investment Management LLC (1.84%), BVF Inc. IL (1.79%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $40.55. How much money does Ionis Pharmaceuticals make? Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.80 billion and generates $575.97 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. How many employees does Ionis Pharmaceuticals have? The company employs 660 workers across the globe. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700. This page (NASDAQ:IONS) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.